Ovarian Cancer

U.S. FDA grants orphan drug status to combretastatin A4P for treating ovarian cancer

Published in Cancer Weekly, June 12th, 2006

OXiGENE, Inc. (OXGN), a developer of biopharmaceutical compounds to treat cancer and certain ophthalmologic diseases, announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to the company's lead vascular disrupting agent combretastatin A4P (CA4P) for the treatment of ovarian cancer.

CA4P is being evaluated in a phase 2 clinical trial in combination with the widely used chemotherapy regimen, carboplatin and paclitaxel, for the treatment of platinum resistant ovarian cancer. Results previously reported from a phase 1b clinical trial showed a 67% response rate to the combined...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry